SCHEMBL406252

SCHEMBL406252

COc1cccc(NCC(O)Cn2c3ccc(Br)cc3c3cc(Br)ccc32)c1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSPO P30536 3/20 0.77
DNM1 Q05193 10/20 0.71
MAPT P10636 5/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
KMT2A Q03164 4/20 0.49
MEN1 O00255 3/20 0.49
TDP1 Q9NUW8 2/20 0.49
HTT P42858 2/20 0.49
NPSR1 Q6W5P4 2/20 0.49
ALDH1A1 P00352 2/20 0.49
GAA P10253 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
CYP1A2 P05177 1/20 0.48
CYP2C19 P33261 1/20 0.48
OPRM1 P35372 1/20 0.48
LMNA P02545 1/20 0.45
TP53 P04637 1/20 0.45
MAPK1 P28482 1/20 0.45
P2RX3 P56373 1/20 0.45
RAD52 P43351 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL410621 1.00 TSPO (0.77) TSPODNM1MAPTSMN1; SMN2KMT2A
SCHEMBL407526 1.00 TSPO (0.77) TSPODNM1MAPTSMN1; SMN2KMT2A
SCHEMBL411251 0.96 TSPO (0.71) TSPODNM1MAPTSMN1; SMN2KMT2A
SCHEMBL407490 0.95 TSPO (0.70) TSPODNM1MAPTSMN1; SMN2KMT2A
SCHEMBL18721999 0.94 TSPO (0.68) TSPODNM1MAPTSMN1; SMN2KMT2A
SCHEMBL30940007 0.91 TSPO (0.65) TSPODNM1MAPTSMN1; SMN2KMT2A
SCHEMBL17932994 0.91 TSPO (0.65) TSPODNM1MAPTSMN1; SMN2KMT2A
SCHEMBL28228400 0.91 TSPO (0.62) TSPODNM1MAPTSMN1; SMN2KMT2A
SCHEMBL30897308 0.91 TSPO (0.64) TSPODNM1MAPTSMN1; SMN2KMT2A
SCHEMBL28641677 0.91 TSPO (0.64) TSPODNM1MAPTSMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 174 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180318255-A1 Pro-Neurogenic Compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2018-11-08 US claimed
EP-2590647-B1 PRO-NEUROGENIC COMPOUNDS UNIV TEXAS (US) 2017-11-08 EP claimed
US-20170157092-A1 Anti-depression Compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2017-06-08 US claimed
US-20160362372-A1 PRO-NEUROGENIC COMPOUNDS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2016-12-15 US claimed
US-20160206594-A1 Pro-Neurogenic Compounds NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-07-21 US claimed
US-20160206596-A1 Anti-depression Compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2016-07-21 US claimed
US-20150290195-A1 PRO-NEUROGENIC COMPOUNDS BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2015-10-15 US claimed
EP-2925129-A1 PRO-NEUROGENIC COMPOUNDS Board of Regents of the University of Texas System (US) 2015-10-07 EP claimed
US-20150057301-A1 Pro-Neurogenic Compounds NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-02-26 US claimed
US-20140343018-A1 Anti-depression Compounds NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2014-11-20 US claimed
US-20130184301-A1 Methods of Treating Post-Traumatic Stress Disorder Using Pro-Neurogenic Compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2013-07-18 US claimed
EP-2590647-A2 PRO-NEUROGENIC COMPOUNDS Board of Regents of the University of Texas System (US) 2013-05-15 EP claimed
US-20130040977-A1 Pro-Neurogenic Compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2013-02-14 US claimed
US-20120022096-A1 PRO-NEUROGENIC COMPOUNDS BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2012-01-26 US claimed
WO-2012006419-A2 PRO-NEUROGENIC COMPOUNDS BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2012-01-12 WO claimed
EP-2385829-A1 PRO-NEUROGENIC COMPOUNDS Board of Regents of the University of Texas System (US) 2011-11-16 EP claimed
US-8039041-B2 Electroluminescent devices with electrode protection CAMBRIDGE DISPLAY TECHNOLOGY, LTD. (GB) 2011-10-18 US claimed
US-20110015217-A1 Pro-Neurogenic Compounds BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2011-01-20 US claimed
US-20110003836-A1 Pro-Neurogenic Compounds BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2011-01-06 US claimed
WO-2010081115-A1 PRO-NEUROGENIC COMPOUNDS UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER (US) 2010-07-15 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130184301-A1 Methods of Treating Post-Traumatic Stress Disorder Using Pro-Neurogenic Compounds BDNF, GAP43, DCX TSPO 478/4885DNM1 1086/4885MAPT 578/4885
US-20120022096-A1 PRO-NEUROGENIC COMPOUNDS BDNF, GAP43, DCX TSPO 2470/4885DNM1 897/4885MAPT 136/4885
US-20160206594-A1 Pro-Neurogenic Compounds DCX, GAP43, BDNF TSPO 826/4885DNM1 510/4885MAPT 559/4885
US-20150057301-A1 Pro-Neurogenic Compounds DCX, GAP43, BDNF TSPO 671/4885DNM1 625/4885MAPT 620/4885
US-20180318255-A1 Pro-Neurogenic Compounds BDNF, GAP43, DCX TSPO 2470/4885DNM1 897/4885MAPT 136/4885
US-20110015217-A1 Pro-Neurogenic Compounds DCX, GAP43, BDNF TSPO 826/4885DNM1 510/4885MAPT 559/4885
US-20150290195-A1 PRO-NEUROGENIC COMPOUNDS DCX, GAP43, BDNF TSPO 826/4885DNM1 510/4885MAPT 559/4885
US-20140343018-A1 Anti-depression Compounds BDNF, DCX, GAP43 TSPO 2600/4885DNM1 638/4885MAPT 142/4885
US-20130040977-A1 Pro-Neurogenic Compounds BDNF, GAP43, DCX TSPO 2470/4885DNM1 897/4885MAPT 136/4885
US-20110003836-A1 Pro-Neurogenic Compounds DCX, GAP43, BDNF TSPO 794/4885DNM1 538/4885MAPT 571/4885
US-20160362372-A1 PRO-NEUROGENIC COMPOUNDS DCX, GAP43, BDNF TSPO 826/4885DNM1 510/4885MAPT 559/4885
US-20160206596-A1 Anti-depression Compounds BDNF, DCX, GAP43 TSPO 2600/4885DNM1 638/4885MAPT 142/4885
US-20170157092-A1 Anti-depression Compounds BDNF, DCX, GAP43 TSPO 2600/4885DNM1 638/4885MAPT 142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.